Gotham Asset Management LLC raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 118.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 924,289 shares of the biotechnology company’s stock after buying an additional 501,828 shares during the period. Gotham Asset Management LLC owned 0.32% of Exelixis worth $20,029,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Fortaleza Asset Management Inc. acquired a new position in Exelixis during the first quarter valued at approximately $106,000. Pittenger & Anderson Inc. acquired a new position in Exelixis during the fourth quarter valued at approximately $149,000. Commerzbank Aktiengesellschaft FI acquired a new position in Exelixis during the fourth quarter valued at approximately $169,000. Meeder Asset Management Inc. acquired a new position in Exelixis during the first quarter valued at approximately $170,000. Finally, Atlantic Trust Group LLC acquired a new position in Exelixis during the first quarter valued at approximately $216,000. Hedge funds and other institutional investors own 80.69% of the company’s stock.
Exelixis, Inc. (EXEL) traded up 0.10% during mid-day trading on Friday, hitting $19.26. 3,678,824 shares of the stock were exchanged. The company has a 50 day moving average price of $20.52 and a 200 day moving average price of $19.79. Exelixis, Inc. has a 52 week low of $7.20 and a 52 week high of $24.85. The stock has a market cap of $5.63 billion, a price-to-earnings ratio of 917.14 and a beta of 1.98.
Exelixis (NASDAQ:EXEL) last announced its earnings results on Monday, May 1st. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. The firm had revenue of $80.90 million during the quarter, compared to analysts’ expectations of $65.23 million. Exelixis had a return on equity of 126.82% and a net margin of 1.37%. The company’s revenue was up 425.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.27) earnings per share. Analysts expect that Exelixis, Inc. will post $0.18 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Gotham Asset Management LLC Raises Position in Exelixis, Inc. (EXEL)” was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://sleekmoney.com/gotham-asset-management-llc-raises-position-in-exelixis-inc-exel/1916449.html.
Several research firms recently commented on EXEL. Zacks Investment Research lowered shares of Exelixis from a “buy” rating to a “hold” rating in a report on Wednesday, March 1st. Stifel Nicolaus lowered shares of Exelixis from a “buy” rating to a “hold” rating and set a $22.00 price target on the stock. in a report on Tuesday, February 28th. They noted that the move was a valuation call. Cann restated a “hold” rating on shares of Exelixis in a report on Wednesday, April 19th. CIBC began coverage on shares of Exelixis in a report on Thursday, March 16th. They issued a “market perform” rating on the stock. Finally, Oppenheimer Holdings, Inc. restated a “market perform” rating on shares of Exelixis in a report on Friday, April 21st. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Exelixis presently has a consensus rating of “Buy” and an average target price of $18.37.
In other Exelixis news, Director Stelios Papadopoulos sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $21.66, for a total transaction of $216,600.00. Following the completion of the sale, the director now owns 1,238,471 shares of the company’s stock, valued at $26,825,281.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patrick J. Haley sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $18.46, for a total value of $92,300.00. The disclosure for this sale can be found here. Insiders have sold 765,468 shares of company stock valued at $16,847,040 in the last ninety days. Company insiders own 5.10% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/gotham-asset-management-llc-raises-position-in-exelixis-inc-exel/1916449.html
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.